Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer.

Saved in:
Bibliographic Details
Title: Mutant p53 epigenetically rewires CXCL10 to promote CD8⁺ T-cell infiltration and enhance the anti-PD-1 response in advanced prostate cancer.
Authors: Chen J; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Ge Q; Department of Urology, Fudan University Shanghai Cancer Center; Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.; Shanghai Genitourinary Cancer Institute, Shanghai, 200032, P. R. China., He J; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Bian Z; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Yu H; Department of Statistics and Data science, College of Letter and Science, University of California Santa Barbara, 552 University Road, Santa Barbara, CA, 93106, United States of America., Li C; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Meng J; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Yin S; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Hao Z; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China., Liang C; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China. liang_chaozhao@ahmu.edu.cn., Zhang M; Department of Urology, The First Affiliated Hospital of Anhui Medical University, Institute of Urology, and Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Jixi Road 218, Shushan District, Hefei, Anhui, 230022, People's Republic of China. zhangmeng@ahmu.edu.cn.
Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2026 Mar 03; Vol. 45 (1). Date of Electronic Publication: 2026 Mar 03.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1756-9966
DOI:10.1186/s13046-026-03672-z